Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).
Jochen
J
Greiner
Vanessa
V
Schneider
Michael
M
Schmitt
Marlies
M
Götz
Konstanze
K
Döhner
Markus
M
Wiesneth
Hartmut
H
Döhner
Susanne
S
Hofmann
D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology; D002467:Cell Nucleus / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology*; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics* / Q000276:immunology; D000090243:Nucleophosmin; D010455:Peptides / Q000276:immunology; D011379:Prognosis; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D019496:Cancer Vaccines; D000939:Epitopes; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D010455:Peptides; D000090243:Nucleophosmin